Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 0.47 |
| ▸ | AGXT | P21549 | 9/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4380427 | 0.98 | IDO1 (0.48) | IDO1AGXTCYP3A4 | |
| SCHEMBL13172967 | 0.82 | PTGDR2 (0.46) | DPP4DPP8TRPV4 | |
| SCHEMBL31126027 | 0.79 | LOXL2 (0.47) | DPP4DPP8TRPV4 | |
| SCHEMBL51299 | 0.79 | LOXL2 (0.47) | DPP4DPP8TRPV4 | |
| SCHEMBL24872544 | 0.79 | TRPV4 (0.45) | DPP4DPP8TRPV4 | |
| SCHEMBL19387955 | 0.78 | RORC (0.42) | DPP4DPP8TRPV4 | |
| Ammonia Solution, Strong SCHEMBL51625 | 0.78 | LOXL2 (0.45) | DPP4DPP8TRPV4 | |
| SCHEMBL1240018 | 0.78 | TAAR1 (0.47) | DPP4DPP8TRPV4 | |
| SCHEMBL13179910 | 0.77 | TRPV4 (0.44) | DPP4DPP8TRPV4 | |
| SCHEMBL10102079 | 0.77 | IDO1 (0.58) | IDO1AGXTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | IDO1 305/4885AGXT 3147/4885CYP3A4 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.